July 10, 2007

The common shares of Immunall Science Inc ("ISI") have been approved for listing on CNQ. There are approximately 30.5 million shares outstanding with a public float of 6.9 million shares.

By way of agreement, ISI has exclusive ownership of a process developed by APA Bioceuticals for separating certain components out of North American ginseng . The product, ginse, has been registered with Health Canada for a Health Product Number and has been assigned a Submission Receipt Acknowledgement number allowing ISI to market the product in Canada.  Ginse can be added to almost any food product with the same result as if it is consumed in a capsule.  ISI will focus on finding companies already selling health products for humans, pets or feedlot animals with the objective of having them either incorporate ginse into one of their products or introduce a new product to an established line already in the marketplace with a known brand name.

ISI also owns 49% of Precise Hydroponics Inc. ("PHI") which owns proprietary information that will allow ISI to grow North American Ginseng hydroponically.  This technology also allows ISI to increase the strength of the biomarkers which are key to ginse's efficacy, thus making the product more effective and at the same time providing a reliable supply of raw material of consistent quality.

Listing and disclosure documents for Immunall Science Inc. will be available in the CNQ Listings Disclosure Hall

Pursuant to CNQ Policy 2, ISI has been designated as a "thin float issuer".

Trading Date: Thursday, July 12, 2007
Symbol: GNSE
CUSIP: 45252P 10 4

Applications are being accepted for Market Makers for "GNSE". If you have any questions or require further information please contact Radhika Ramkarran at (416) 572-2000 X 2435 or E-mail: radhika.ramkarran@cnq.ca